Bioconjugation of oligonucleotides with GalNAc is a well-established approach for targeting hepatocytes via the asialoglycoprotein receptor (ASGPR, abundantly expressed on the hepatocyte surface) for treatment of various liver diseases. The gene discussed is ASGR1; the disease is liver disorder.